Objectives This study evaluated safety and efficacy of upfront thrombus aspiration during primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI).
Reperfusion therapy in patients presenting with STsegment elevation myocardial infarction (STEMI) remains suboptimal. Abnormal tissue-level myocardial perfusion has been shown to increase infarct size and reduce survival, in spite of successful epicardial coronary reperfusion (1) (2) (3) (4) (5) (6) (7) . Thus, approaches to improve results of primary percutaneous coronary intervention (PCI) have been proposed. Primary PCIs facilitated by various adjunctive pharmacological therapies have been attempted, but the benefit of such strategies is questionable (8 -10) . The hypothesis that distal protection or thrombectomy in addition to primary PCI improve myocardial salvage in patients with STEMI has also been attempted (11) (12) (13) . Similarly, these studies failed to demonstrate a clear benefit of thrombectomy (11) (12) (13) . The results of these previous investigations challenge our current understanding of the importance of thrombus embolism as the cause of microvascular dysfunction and poor outcomes after reperfusion therapy (14 -19) . Failure to effectively aspirate materials, inadequate timing of deployment of distal protection devices or use of these devices without upfront aspiration, and typical learning curve for handling new devices particularly in emergency situations may have contributed to the perceived failure of thrombectomy strategies in previous studies. The TransVascular Aspiration Catheter (TVAC) (Nipro, Osaka, Japan) has a unique distal tip in the shape of a duck bill and possesses a wide aspiration lumen, which should improve aspiration performance (20) . This device has been tested previously and showed good technical performance (20) . Thus, the present study was planned to evaluate the safety and efficacy of upfront thrombus aspiration strategy using the novel TVAC device in patients with STEMI.
Methods
Study design and eligibility. The VAMPIRE (VAcuuM asPIration thrombus REmoval) study was a prospective randomized multicenter trial performed in compliance with the provisions of the Declaration of Helsinki regarding clinical investigations in humans. The study was approved by the institutional review boards of all the investigational sites and written informed consent was obtained from all patients. Patients were enrolled from July 1, 2003, to January 1, 2005, and followed up to January 1, 2006 . Patient randomization and study flow are shown in Figure 1 .
Individuals eligible for enrollment were 21 years old or older with acute myocardial infarction presenting more than 30 min but Ͻ24 h after symptom onset, with 2 mm or more of STsegment elevation in 2 or more contiguous leads or with a presumably new left bundle-branch block. Major criteria for exclusion were presence of primary thrombolysis prior to randomization, cardiogenic shock, history of cardiac arrest, history of coronary bypass surgery, chronic renal failure (Cr Ͼ2.0 mg/dl) or hemodialysis, left main disease, or target vessel Ͻ2.5 mm or Ͼ5 mm in diameter. There were no further exclusion criteria. PCI procedure. Patients were pretreated with aspirin and intravenous heparin boluses were administered during the procedure to maintain an activated clotting time Ն300 s. The PCI was performed according to standard techniques with the use of 7-F guiding catheters. Aspiration was performed using TVAC, which is a single lumen rapidexchange aspiration shaft, compatible with 7-F guiding catheters and has a dedicated vacuum pump (20) . No aspiration was performed prior to or following PCI in the control group. The use of bare metal stents was at the discretion of the attending physicians and the goal was to achieve Thrombolysis In Myocardial Infarction (TIMI) The primary end point of this study was the incidence of slow flow or no reflow during primary PCI defined as a TIMI flow grade Ͻ3 not attributable to dissection, occlusive thrombus, or epicardial spasm that was evaluated by an independent core laboratory. Secondary end points were coronary flow and myocardial perfusion immediately after PCI, as assessed by TIMI flow grade, corrected TIMI frame count (cTFC), and myocardial blush score.
Other secondary end points were time and magnitude of ST-segment resolution, peak creatine kinase (CK) and creatine kinase-myocardial band (CK-MB) measured every 8 h for 24 h after the procedure, angiographic in-stent late lumen loss at 6 months, left ventricular function as determined by angiography at 6 months, brain natriuretic peptide levels at 6 months, and major adverse clinical events as a composite of death, recurrence of myocardial infarction, and target lesion revascularization over 8 months. All patients were scheduled for angiographic follow-up at 6 months and clinical visits at 1, 3, 6, and 8 months. Data analysis was performed by an independent clinical research organization (Cardiocore Japan, Tokyo, Japan). Clinical events were adjudicated by an independent committee. Angiographic analysis. Coronary angiograms were analyzed by an independent core laboratory (K. Kozuma, MD, at Cardiocore Japan). Analysts were blinded to clinical data. Angiographic TIMI flow grade was estimated visually, using standardized procedures. The cTFC was measured with a frame counter on a digital film viewer analyzing the number of cine frames required for contrast to reach a standardized landmark. Results were corrected for 30 frames/s and the frame counts for the left anterior descending artery were divided by 1.7 because of the difference in length, as described previously (21) . In the presence of an occluded vessel (visual TIMI flow grade 0 to 1), cTFC was set to a value of 100. The occurrence of slow flow or no reflow (TIMI flow grade decreasing from 2 or 3 to 0 or 1 during the procedure) was assessed. Myocardial blush grade was assessed immediately after the procedure and at the 6-month follow-up. The TIMI flow, cTFC, and myocardial blush grade were assessed as described previously (2,3,21,22), in each case by 2 experienced analysts following specific standard operating procedures of the core laboratory. Interobserver variability of the blush score was 91% between the 2 analysts involved in this study. In cases of disagreement between assessments from different analysts, reassessment was performed together until consensus was obtained. Quantitative coronary angiography and left ventriculography were performed by means of QCACardiovascular Measurement System, version 5.1 (MEDIS, Leiden, the Netherlands). Distal embolization was defined as the migration of a filling defect or the distal occlusion of the target vessel or 1 of its branches at the end of procedure. Electrocardiographic (ECG) analysis. A 12-lead ECG was acquired at admission, immediately after PCI, 3 to 6 h after PCI, at discharge, and 6 months after PCI. The ECG was analyzed by an independent core laboratory (Cardiocore Japan). The ST-segment levels were measured 60 ms after the J point in the most abnormal lead. The percentage resolution of ST-segment elevation was categorized using the Schroder classification as complete (Ͼ70%), partial (30% to 70%), or absent (Ͻ30%) (23, 24) . Statistical methods. The test hypothesis was that the incidence of the primary end point in the control group is higher than in the study group. We estimated a 25% incidence of slow flow or no reflow in the control group, taking into consideration the range of previously reported data in similar populations (23% to 37%) (1, 25, 26) . We expected an 11% incidence of slow flow/no flow in the aspiration group, based on previous observations (27) and on our own unpublished data. Thus, a total sample size of 171 patients in each arm would provide 90% power to detect a difference in the primary end point between groups ( 1 ϭ 11%; 2 ϭ 25%) using 2 group chi-square tests with a 0.05 2-sided significance level. Considering potential dropouts during the study, the sample size in each arm was set at 175 patients. All analyses were performed according to the intent-to-treat principle. Categorical variables were presented as frequency values and were compared using the chi-square test. Continuous variables were expressed as mean Ϯ standard deviation and were compared by using the Student t test.
Results
From July 1, 2003, to January 1, 2005, 362 patients were enrolled. Seven patients were excluded from the study after the enrollment: 2 because of errors in the diagnosis of STEMI, 2 withdrew the informed consent, and 3 patients were protocol violations due to inadequate coronary artery diameters. A total of 355 patients with STEMI within 24 h of symptoms onset were randomized to receive either PCI with thrombus aspiration using TVAC (n ϭ 180) or PCI alone (n ϭ 175) at 23 hospitals in Japan. Baseline clinical and angiographic characteris-
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tics were well matched between the 2 randomized groups (Tables 1 and 2) . Procedural results. The TVAC reached the lesion in 100% of the patients as a primary device, but operators were able to cross the target obstruction with the TVAC without pre-dilation in 83% of cases. In 3% of cases, device crossing was achieved after balloon dilation. The TIMI flow grade 2 or 3 immediately after aspiration was achieved in 90.7% of patients randomized to aspiration as compared with 47.4% after pre-balloon wire manipulation in the control group. There were no coronary perforations in either group. There were no differences in procedural success rate, time from catheterization laboratory door to TIMI flow grades 2 or 3, or procedural time ( Table 2 ). The incidence of coronary dissection and final distal embolism rate was significantly lower in the aspiration group. Macroscopic thrombus and/or plaque debris were removed in 75.6% of cases (42.5% of red thrombus, 18.7% of white thrombus, 10.6% of red and white thrombus, and 3.1% of yellow plaques and white thrombus). Myocardial reperfusion end points. Angiographic measures of myocardial perfusion were generally better in patients treated with thrombectomy and primary PCI compared with standard therapy (Table 3 ). The primary end point, rate of slow flow or no reflow, was achieved in 12.5% of patients in the aspiration group versus 19.4% in the control group (p ϭ 0.07) ( Table 3 , Fig. 2 ). Myocardial blush grade was significantly better in the thrombus aspiration group compared with conventional primary PCI (p Ͻ 0.001). There was no significant difference in ST-segment resolution, peak CK or peak CK-MB release between the 2 groups (Table 3) . Other angiographic end points. Data is presented in Table 4 . Quantitative analyses of the target vessel and left ventricular function at baseline or follow-up were similar between groups (Table 4 ). Brain natriuretic peptide levels at 6 months showed a lower number in the aspiration group compared with the control, though the difference did not reach statistical significance. Clinical outcome. During hospitalization, 1 patient died in each group. Another patient had subacute thrombosis and complicated repeat myocardial infarction in the control group. The 8-month major adverse cardiac event rate was significantly lower in the thrombus aspiration group (12.9% vs. 21.0%, p Ͻ 0.05) mainly due to low target lesion revascularization rates in patients with late reperfusion of between 6 and 24 h (Table 5) . Subgroup analysis of early and late reperfusion. Patients were stratified into an early (Ͻ6 h from symptoms) and a late (Ͼ6 h from symptoms) reperfusion. The strategy of thrombectomy and primary PCI produced consistent improvement in all angiographic and clinical outcome measures compared with conventional primary PCI in patients presenting late after STEMI (Table 6 ). 

Discussion
The strategy of primary PCI with upfront thrombus aspiration using the TVAC device may be safe and was associated with improved clinical outcomes in the VAM-PIRE study. There was a trend toward better reperfusion parameters, including the primary end point of slow or no reflow phenomena during PCI, among patients who underwent aspiration. In particular, patients presenting between 6 and 24 h after symptoms onset appear to benefit the most from the thrombectomy strategy used in the present study. This subgroup of patients experienced better reperfusion parameters and lower incidence of adverse clinical events when treated with aspiration as compared with conventional primary PCI. The rate of slow or no reflow was 6 percentage points lower in the control population than anticipated, which may explain the reduced statistical power to detect statistical differences in the primary end point between groups. Recent studies reported after the initiation of our trial have shown similarly low rates of slow flow rates (11% to 13%) in patients treated with conventional primary PCI without thrombectomy or distal protection (1-3).
In the published randomized studies so far, the AiMI (A Prospective, Randomized, Controlled Trial of Thrombectomy with the AngioJet in Acute Myocardial Infarction) trial tested the benefit of AngioJet as an adjunct to direct PCI in 480 patients with STEMI. The group randomly assigned to the AngioJet group had significantly larger infarct sizes, worse angiographic measures, and a higher incidence of adverse clinical events than patients assigned to the usual care group. Furthermore, the extensive use of pacemakers might have contributed to poor outcomes increasing the risks of cardiac tamponade in the AiMI trial. In the VAMPIRE trial, the baseline infarct sizes and angiographic measures were similar between the groups and pacemaker use was not extensive. In the DEAR-MI (Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction) trial (28) , the use of catheter thrombectomy in a randomized study of 148 patients with STEMI was associated with better myocardial reperfusion, lower CK release, lower risk of distal embolization, and lower risk of no reflow. The results of the DEAR-MI trial were consistent with the VAMPIRE study. In the X-AMINE ST (X-Sizer Table 2 . The primary end point of this study was the magnitude of ST-segment resolution at 1 h, which was improved in the X-Sizer group compared with the conventional therapy group (7.5 mm vs. 4.9 mm, p ϭ 0.033). Although the occurrence of distal embolization was reduced with the use of X-Sizer (2% vs. 10%), equivalent rates were seen for TIMI flow grade 3, myocardial blush grade 3, and 6-month major adverse cardiac and cerebral events. In the X-TRACT (Prospective Randomized Trial of Thromboatherectomy with the X-Sizer in Native Coronary Arteries and Saphenous Vein Grafts) study (30) , a total of 797 consecutive patients undergoing stent implantation in vein grafts (72%) or native coronary artery containing thrombus (28%) were prospectively randomized to X-Sizer catheter or to usual care followed by PCI groups. The rates of no reflow, distal emboli, myocardial infarction, as well as 30-day rate of major adverse cardiac events were similar between the groups. Despite of the marginal 36% difference in the incidence of the primary end point between groups, the VAMPIRE study showed several potential benefits of the upfront aspiration as reported in other studies (31) (32) (33) . The TIMI flow grades 2 or 3 were achieved in 90% of cases immediately after aspiration, which may facilitate selection of PCI device sizes as it provides early information about the size of distal artery as well as location and length of the target Early reperfusion included patients who arrived at hospital within 6 h from the onset. Late reperfusion included patients who arrived at hospital from 6 h to 24 h from the onset.
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Abbreviations as in Tables 1, 2 lesion. The higher incidence of TIMI flow after aspiration may also help explain the lower coronary dissection observed in the treatment arm. The procedure time or time to reperfusion was not affected by the use of 1 additional device in the TVAC group. The time to perform thrombectomy and primary PCI in the present study is relatively shorter than in previous reports, which may explain the difference in outcomes between studies (11) (12) (13) 29) . Furthermore, there was a high rate of macroscopic thrombus or plaque debris aspirated in our study. The flexibility, low crossing profile, and the activation of suction during insertion of the TVAC catheter prior to crossing the obstruction, may have resulted in lower distal embolism in this study. Although a major adverse clinical event was not a primary end point of this study, the 38% reduction in the incidence of clinical events, primarily due to lower target lesion revascularization rates, observed in the aspiration group is noticeable. Whether removal of inflammatory debris and active thrombus material from the target lesion prior to stenting explain the low clinical restenosis rates observed in the present study remains to be confirmed by studies properly designed to test such a hypothesis. Finally, our study provides strong pilot evidence that patients presenting late after symptoms onset benefit the most from upfront thrombectomy during primary PCI. Conventional primary PCI in this subgroup is associated with worse outcomes than in those presenting earlier after symptoms (34) . Conversely, angiographic and clinical outcomes were essentially equalized between early and late reperfusion patients when both populations were treated with a strategy of upfront thrombectomy prior to primary PCI. Study limitations. Not using glycoprotein IIb/IIIa inhibitors may be a limitation of this study because their use could influence outcomes whose pathogenesis involves platelet thrombi. However, the use of glycoprotein IIb/IIIa inhibitors has not uniformly produced enhanced clinical outcomes in clinical trials (35) . Future studies could investigate the interaction between glycoprotein IIb/IIIa inhibitors and thrombectomy devices in the setting of STEMI.
Conclusions
The VAMPIRE study showed the marginal benefit of thrombectomy on myocardial perfusion. In a post hoc analysis, patients with late reperfusion of between 6 and 24 h benefited most from the thrombectomy. The effectiveness of thrombectomy for STEMI may deserve reevaluation with a simple upfront thrombus aspiration strategy using an efficient device in a refined study design.
The study was not designed, and consequently is underpowered, to detect major differences in isolated clinical end points such as myocardial infarction and death. Our data may not apply to the overall population presenting with STEMI as differences in specific technical aspects of the procedure, such as time to balloon inflation, aspiration devices, and mode of aspiration may differ between institutions and countries. Nevertheless, our results support the concept that upfront thrombectomy in patients with acute STEMI undergoing primary PCI is safe and may improve acute reperfusion and clinical outcomes, particularly in patients presenting later after symptoms onset. Taken together, the knowledge accumulated with other studies investigating similar hypotheses and the present data warrant further attempts to develop rheolytic strategies to improve outcomes of the high-risk population presenting with STEMI.
